Format

Send to

Choose Destination
Immunol Lett. 2018 Nov;203:95-101. doi: 10.1016/j.imlet.2018.09.014. Epub 2018 Sep 25.

Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery.

Author information

1
Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
2
Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
3
Department of Otolaryngology, University of Pavia and Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
4
Service of Biostatistics Hematology Department, Niguarda Ca' Granda Hospital, Milan, Italy.
5
Department of Medicine, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy. Electronic address: gio.cip@libero.it.
6
Department of Pediatrics, University of Parma, Parma, Italy.

Abstract

Respiratory infections, mainly in children, are a demanding challenge for physicians. Commonly, a relative immune-defect sustains their recurrence. At present, there is no standardized treatment for their prevention acting on the immune system. Citomix is a low-dose multicomponent medication largely used in this issue. The current study evaluated its ex vivo effect on adenoidal mononuclear cells recovered from children operated for adenoid hypertrophy. B cell phenotype, and IFN-γ, IL-6, IL-10, IgG, IgA, IgM in culture supernatants were evaluated. Citomix was able to significantly increase the expression of B memory cells, IFN-γ, IL-6, IgA and IgM, and significantly decrease IL-10 and IgG. The current outcomes could be consistent with a strategy deputed to improve the early immune response to pathogens. In conclusion, the present ex vivo study suggests that Citomix might be a promising medication in preventing and early treating respiratory infections.

KEYWORDS:

Adenoidal cells; B memory cells; Children; IFN-γ; IL-10; IL-6; IgA; IgG; IgM; Low-dose multicomponent medication; Respiratory infections; SKA (sequential kinetic activation)

PMID:
30261195
DOI:
10.1016/j.imlet.2018.09.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center